logo
IonQ, D-Wave, and Rigetti Face Off Ahead of Earnings – Who's Nearest to Commercial Breakthrough?

IonQ, D-Wave, and Rigetti Face Off Ahead of Earnings – Who's Nearest to Commercial Breakthrough?

In just three weeks, Wall Street will get another look under the hood of three of its most closely watched pure-play quantum computing stocks. IonQ (IONQ), D-Wave Quantum (QBTS), and Rigetti Computing (RGTI) are all slated to report second-quarter earnings, offering fresh insight into their progress toward commercial viability. Each company is navigating the road to quantum relevance in its own way, and with investor expectations evolving, this round of results could help clarify which names are gaining ground and which are still stuck in the lab.
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
First is IonQ, which has built the most ambitious roadmap of the three. It has also struck high-profile partnerships with AstraZeneca (AZN), Amazon Web Services (AMZN), and Nvidia (NVDA), backing its trapped-ion architecture. The company is actively involved in enterprise research in pharma, aerospace, and artificial intelligence. It's also investing in a dedicated quantum computer factory to scale hardware for commercial delivery, targeting interconnected quantum systems by 2028.
Recent acquisitions, including Oxford Ionics and Lightsynq, strengthen its hardware stack and roadmap for networking quantum systems. Revenue growth has been steady since 2021, and although IonQ remains unprofitable, its trajectory shows growing market traction. Analyst sentiment is optimistic. Five analysts rate it a Buy, one a Hold. The average 12-month price target is $43, about 3.7% above the current price of $41.47.
D-Wave: Visible Path to Commercialization
D-Wave Quantum is the only company in the group with confirmed commercial sales of its hardware. Its Q1 2025 revenue reached $15 million, a 500% increase year-over-year, driven by a direct sale to a commercial customer. The company's 'Advantage2' platform achieved quantum supremacy on an optimization task, transitioning from a pilot stage to operational use cases in logistics and manufacturing.
D-Wave is also expanding its Quantum Compute as a Service (QCaaS) business, which supports recurring revenue and makes its commercialization path more visible. Analysts are broadly supportive, with seven Buys and no Holds or Sells. The average price target is $17.33, reflecting a 7.3% upside from the current price of $16.15.
Rigetti: Commercial Outlook Still Lagging
Rigetti Computing is the most research-focused of the three. Its superconducting qubit architecture is technically solid, but the company remains tied to government and academic revenue. A $100 million partnership with Quanta Computer may accelerate development, but broader commercialization still depends on solving key fidelity and scalability challenges. Revenue in Q1 2025 came in at just $1.47 million. Although Rigetti posted net income of $42.6 million, that gain was tied to other income and not recurring operations.
Rigetti's stock is down more than 16% year-to-date. Analysts remain bullish, with seven Buys and an average price target of $15, implying 17.9% upside from the current $12.72 price. But the commercial outlook still lags behind.
Conclusion
D-Wave Quantum is currently the most commercially active, having already closed real customer deals. IonQ has broader partnerships and a deeper long-term roadmap, positioning it as a potential platform leader. Rigetti, while technologically credible, remains focused on research and government contracts, with its path to widespread commercial adoption still taking shape. Ahead of Q2 earnings, investors may watch for updates on commercial traction, client pipelines, and revenue expansion to gauge who is truly closing in on quantum's commercialization moment.
Using TipRanks' Comparison Tool, we've assembled and compared the three stocks – IONQ, RGTI, and QBTS, to gain a broader look at each stock's overall standings.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Impulse Dynamics® Completes Enrollment of Pivotal Trial for CCM-D® HF System and Earns Category 1 CPT Codes for CCM® Therapy
Impulse Dynamics® Completes Enrollment of Pivotal Trial for CCM-D® HF System and Earns Category 1 CPT Codes for CCM® Therapy

Hamilton Spectator

time2 hours ago

  • Hamilton Spectator

Impulse Dynamics® Completes Enrollment of Pivotal Trial for CCM-D® HF System and Earns Category 1 CPT Codes for CCM® Therapy

MARLTON, N.J., July 28, 2025 (GLOBE NEWSWIRE) — Impulse Dynamics®, a global medical device company committed to improving the lives of people with heart failure (HF), announced two major accomplishments, marking an inflection point in the advancement and accessibility of CCM® Therapy. 'We are proud to achieve these two pivotal milestones, which signal the growing acceptance of CCM® Therapy as a core component of HF treatment,' said Jason Spees, CEO of Impulse Dynamics®. 'The progress of the INTEGRA-D™ trial moves forward our path to seek regulatory approval of this first-of-its-kind, combined therapy for HF patients. Additionally, we appreciate the support of the ACC and HRS on our CPT coding initiative, and the AMA's timely review process that opens the door to broader access for patients and providers.' 'Many HF patients are treated with ICDs to protect against sudden death, but most do not treat HF itself. The INTEGRA-D™ trial is focused on evaluating a new device aimed at bridging this treatment gap by delivering symptom relief for HF patients receiving ICDs,' said Niraj Varma, M.D., Ph.D., Professor of Medicine and Director of Cardiac Pacing and Tachyarrhythmia at the Cleveland Clinic, and National Principal Investigator of the INTEGRA-D™ clinical trial. 'Completing enrollment for this trial is an important step towards evaluating this device for patients that could potentially benefit.' Each year, over 100,000 new ICDs are implanted in patients in the United States alone, adding to the estimated 800,000 individuals currently living with these devices (1,2). The CCM-D® HF System represents an important advancement, potentially offering these patients an option to life-saving technology and HF symptom relief. Additionally, the availability of CPT codes has expanded reimbursement pathways for the current Optimizer® device, helping increase access to this therapy for individuals living with heart failure, underscoring the maturation of CCM® therapy from an emerging innovation to a potentially established standard of care for HF patients. Together, these two milestones represent Impulse Dynamics®' unwavering focus on driving meaningful innovation for the millions of patients living with HF. About the INTEGRA-D™ Trial The INTEGRA-D™ trial is a multicenter, prospective, single-arm study evaluating the safety and efficacy of CCM-D® HF System. This April, the initial defibrillation efficacy (DE) cohort results were presented by Dr. Niraj Varma as a late-breaking clinical trial at the 2025 Heart Rhythm conference in San Diego, which marked the completion of the efficacy phase of the trial. The CCM-D® device successfully converted induced ventricular fibrillation (VF) in 100 percent of the enrolled patients in the DE cohort, meeting the primary efficacy endpoint. Once six months of follow-up is completed, the data will be submitted to the U.S. Food and Drug Administration (FDA) in a Premarket Approval (PMA) application. About the Optimizer® System and CCM® Therapy The Optimizer® system delivers CCM® therapy — the company's proprietary technology — to the heart, providing clinically meaningful improvement to quality of life for appropriate HF patients. CCM® therapy is designed to significantly improve heart contraction, allowing more oxygen-rich blood to be pushed out through the body[2]. CCM® therapy is indicated to improve six-minute hall walk, quality of life, and functional status of NYHA Class III HF patients who remain symptomatic despite guideline directed medical therapy, are not receiving CRT, and have a left ventricular ejection fraction ranging from 25 to 45 percent. CCM® is the brand name for cardiac contractility modulation — the non-excitatory electrical pulses delivered by the implantable Optimizer® device to improve heart contraction. CCM® therapy sends unique electrical pulses to the heart cells during the absolute refractory period. In doing so, CCM® helps the heart contract more forcibly. Impulse Dynamics® has completed numerous clinical studies, including several randomized controlled trials, the results of which appeared in more than 100 publications in leading medical journals. About Impulse Dynamics® Impulse Dynamics® is dedicated to advancing the treatment of HF for patients and the healthcare providers who care for them. The company pioneered its proprietary CCM® therapy, which uses the Optimizer® technology platform to improve quality of life in HF patients. CCM® therapy is delivered through the Optimizer® system, which includes an implantable pulse generator (IPG) implanted in a minimally invasive procedure and approved for commercial use in the United States and countries worldwide. More than 10,000 patients have received the therapy as part of clinical trials and real-world use, where it is shown to be safe and effective for HF patients with debilitating symptoms who otherwise have few effective options available to them. The company is currently engaged in another significant clinical trial called AIM HIGHer. The AIM HIGHer clinical trial is a multicenter study with the objective to evaluate the safety and efficacy of CCM® therapy in patients with symptomatic HF with an ejection fraction of 40 to 70 percent (inclusive). The trial is currently in its initial enrollment phase. To learn more, visit , or follow the company on LinkedIn, X (formerly Twitter), and Facebook. ### References:

IonQ Appoints Marco Pistoia as Senior Vice President of Industry Relations to Drive Strategic Partnerships, Collaborations, and Quantum Advocacy
IonQ Appoints Marco Pistoia as Senior Vice President of Industry Relations to Drive Strategic Partnerships, Collaborations, and Quantum Advocacy

Business Wire

time3 hours ago

  • Business Wire

IonQ Appoints Marco Pistoia as Senior Vice President of Industry Relations to Drive Strategic Partnerships, Collaborations, and Quantum Advocacy

COLLEGE PARK, Md.--(BUSINESS WIRE)--IonQ (NYSE: IONQ), the leading commercial quantum computing and networking company, today announced the appointment of Dr. Marco Pistoia as Senior Vice President of Industry Relations. Pistoia is a renowned IBM inventor, quantum computing leader, and former Global Head of Applied Research and Quantum Computing at JPMorganChase, where he achieved the rank of Distinguished Engineer — the highest technology title in the bank. He will play a critical leadership role in driving strategic partnerships, collaborations, and advocacy efforts to advance IonQ's position within the quantum computing and quantum networking sectors. 'Marco has long been one of the most influential figures in applied quantum computing and quantum networking,' said Niccolo de Masi, CEO of IonQ. 'His leadership in building the most advanced quantum program in the financial sector, and his track record of pioneering work in quantum cryptography, AI, quantum algorithms, and quantum key distribution (QKD) makes him an ideal fit for IonQ's mission. We're thrilled to welcome him as we continue scaling quantum computing and networking solutions for real-world impact.' At JPMorganChase, Pistoia led the financial industry's most advanced quantum program. Under his leadership, the team developed novel quantum algorithms for optimization, Monte Carlo integration, fraud detection, and AI. He led the first experimental certification of quantum-generated randomness, providing end users with enhanced security and privacy. He also pioneered advances in post-quantum cryptography and QKD, setting a world record with an experimental demonstration of an 800 Gbps QKD-secured link over 100 kilometers upon which JPMorganChase deployed its blockchain application for payments. Before JPMorgan, Pistoia spent over two decades at IBM Research, where he was the Senior Manager of Quantum Algorithms and Applications, Distinguished Research Staff Member, and Master Inventor – a recognition IBM bestows on select employees who have contributed significantly to the company's intellectual property portfolio. He holds 647 patents – including 100 in quantum computing, quantum communications, and quantum-inspired AI/ML algorithms. Additionally, Pistoia has written 10 books and authored more than 200 scientific articles – published in leading journals such as Nature and Science Advances. Pistoia received a Ph.D. in Mathematics from New York University and a BS and MS degree in Mathematics from the University of Rome Tor Vergata. 'IonQ is a leading quantum technology company with a unique combination of world-class hardware, ground-breaking innovations, and advanced application performance,' said Pistoia. 'I'm excited to join the team and contribute to a technology roadmap that prioritizes both scale and security in solving mission-critical problems.' Pistoia's appointment reinforces IonQ's focus on real-world quantum applications and strengthens its leadership as the company continues to scale across industries. About IonQ IonQ, Inc. [NYSE: IONQ] is the leading commercial quantum computing and networking company, delivering high-performance systems aimed at solving the world's most complex problems. IonQ's current generation quantum computers, IonQ Forte and IonQ Forte Enterprise, are the latest in a line of cutting-edge systems that have been helping customers and partners such as Amazon Web Services, AstraZeneca, and NVIDIA achieve 20x performance results. The company is accelerating its technology roadmap and intends to deliver the world's most powerful quantum computers with 2 million qubits by 2030 to accelerate innovation in drug discovery, materials science, financial modeling, logistics, cybersecurity, and defense. IonQ's advancements in quantum networking also positions the company as a leader in building the quantum internet. The company's innovative technology and rapid growth were recognized in Newsweek's 2025 Excellence Index 1000, Forbes' 2025 Most Successful Mid-Cap Companies list, and Built In's 2025 100 Best Midsize Places to Work in Washington DC and Seattle, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature are intended to identify forward-looking statements. These statements include those related to the IonQ's quantum computing capabilities and plans; IonQ's technology driving commercial quantum advantage in the future; the relevance and utility of quantum algorithms and applications run on IonQ's quantum computers; the necessity, effectiveness, and future impacts of IonQ's offerings available today; and the scalability, fidelity, efficiency, viability, accessibility, effectiveness, importance, reliability, performance, speed, impact, practicality, feasibility, and commercial-readiness of IonQ's offerings. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: IonQ's ability to implement its technical roadmap; changes in the competitive industries in which IonQ operates, including development of competing technologies; IonQ's inability to attract and retain key personnel; or IonQ's ability to deliver, and customers' ability to generate, value from IonQ's offerings. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company's filings, including but not limited to those described in the 'Risk Factors' section of IonQ's most recent periodic financial report (10-Q or 10-K) filed by IonQ with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations.

Prediction: Quantum Computing Stock Will Be Worth This Much in 2030
Prediction: Quantum Computing Stock Will Be Worth This Much in 2030

Yahoo

time13 hours ago

  • Yahoo

Prediction: Quantum Computing Stock Will Be Worth This Much in 2030

Key Points Quantum Computing has emerged alongside other popular quantum stocks such as IonQ, Rigetti Computing, and D-Wave Quantum over the last year. While the company's approach to building quantum applications is interesting, past ambitions in other markets and an inconsistent financial profile should make investors pause before blindly buying the hype narrative. Although Quantum Computing has interesting potential, the amount of unknowns surrounding the company's future are hard to ignore. 10 stocks we like better than Quantum Computing › One of the more curious companies that has piqued investor intrigue in the quantum computing market is a business called (wait for it!) Quantum Computing (NASDAQ: QUBT). With a name like that, I wonder how it landed on so many radars. Sarcasm aside, Quantum Computing (the business) deserves a look -- and not just because of its 2,400% share price gains over the last year. To me, the company's technological promises and its actual business just don't align. Let's explore how Quantum Computing is attempting to disrupt the artificial intelligence (AI) realm and then dig into whether or not the company has what it takes to fulfill its lofty ambitions. Is Quantum Computing the next multibagger AI stock? Read on to find out. Quantum Computing might look like an exciting company on the surface, but... Quantum-based applications have the potential to transform the computing industry thanks to their fundamentally differentiated architectures. In simple terms, classical computing is based on binary code, written through a series of bits expressed as 1 or 0. Quantum computing uses qubits, which means they can exist as both 1 and 0 at the same time -- a process known as superposition. This allows for more complex information processing compared to today's classical computers. There are multiple ways that companies are developing qubits. IonQ relies on a process called trapped-ion, which essentially uses lasers to trap atoms and use them as the foundation of a qubit. Meanwhile, other competitors such as Rigetti Computing and D-Wave Quantum use superconducting circuits and quantum annealing techniques to make qubits. Quantum Computing, on the other hand, is using light (photons) as opposed to Rigetti and D-Wave's electricity-based foundation or IonQ's trapped atom technology. In theory, photonic qubits may be more energy efficient and easier to scale than other approaches that are heavily reliant on sophisticated cooling systems. ... there are quite a few red flags to point out Before buying into the idea that Quantum Computing is on the verge of a technological breakthrough, consider the following: Quantum Computing was once known as Innovative Beverage Group Holdings (IBGH). Why did the company pivot from beverages to qubits? Well, consider that IBGH went out of business, and the leftover management team decided to acquire a small company called QPhoton and completely shift its focus to quantum computing. Over the last year, Quantum Computing has generated $385,000 in sales. While the idea of photonic qubits is interesting, Quantum Computing is far from building a competitive moat over its rivals. The company's nominal revenue base and unproven roadmap hint at possible liquidity crunches down the road. For now, Quantum Computing appears to be relying on issuing stock as a means to raise cash and fund the operation. Despite these red flags, Quantum Computing has seen its market value climb from $55 million to $2.4 billion in just one year. The company's valuation is far higher than what investors witnessed during prior stock market bubbles during the internet boom and the COVID-19 stock market euphoria. Where will Quantum Computing stock be in five years? Given the ideas explored above, it's clear that Quantum Computing has virtually nothing to show for its supposed innovative photonic processes. The lack of strategic partners and product-market fit has me thinking that Quantum Computing offers more along the lines of vaporware than anything groundbreaking at this time. With ongoing research and development (R&D) and capital expenditures (capex) required to explore quantum technology, Quantum Computing is likely going to continue tapping the capital markets for liquidity unless some transformative deals begin to take shape -- which I suspect is highly unlikely. In my eyes, Quantum Computing stock is benefiting for one reason above all else. The company's name isn't just associated with one of AI's hottest new themes -- it's literally the name of the actual trend. To me, this is a case study revolving around the idea of investors blindly chasing narratives over sound fundamentals. I think that Quantum Computing is headed toward insolvency and could wind up bankrupt by 2030 (if not sooner). Alternatively, regulators could begin to scrutinize the company more heavily, and Quantum Computing could end up as a delisted stock. Regardless of how things shake out, I think Quantum Computing's equity value will diminish significantly in the coming years. For this reason, I think the company will have little-to-no value by the end of the decade. Should you buy stock in Quantum Computing right now? Before you buy stock in Quantum Computing, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Quantum Computing wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Adam Spatacco has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Prediction: Quantum Computing Stock Will Be Worth This Much in 2030 was originally published by The Motley Fool

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store